Monopar Therapeutics (NASDAQ:MNPR) Issues Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Posted by Brenda Bartman on Aug 14th, 2026

Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) posted its earnings results on Wednesday. The company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.02, Zacks reports.

Monopar Therapeutics Stock Down 3.9%

Monopar Therapeutics stock opened at $110.41 on Friday. The business has a 50 day moving average price of $95.04 and a two-hundred day moving average price of $71.23. The stock has a market cap of $739.75 million, a price-to-earnings ratio of -50.88 and a beta of 1.47. Monopar Therapeutics has a 12 month low of $29.18 and a 12 month high of $124.82.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. bought a new position in Monopar Therapeutics during the third quarter worth about $28,000. BNP Paribas Financial Markets grew its stake in shares of Monopar Therapeutics by 100.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock valued at $57,000 after purchasing an additional 349 shares during the period. Meeder Asset Management Inc. bought a new stake in shares of Monopar Therapeutics in the 4th quarter valued at approximately $65,000. Nuveen LLC raised its holdings in shares of Monopar Therapeutics by 31.5% in the 4th quarter. Nuveen LLC now owns 5,551 shares of the company’s stock worth $362,000 after buying an additional 1,330 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its position in shares of Monopar Therapeutics by 1,821.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock worth $69,000 after buying an additional 1,821 shares during the period. Institutional investors and hedge funds own 1.83% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on MNPR. Cantor Fitzgerald lowered shares of Monopar Therapeutics from an “overweight” rating to a “neutral” rating and increased their price target for the stock from $109.00 to $119.00 in a research note on Thursday. HC Wainwright lifted their price objective on shares of Monopar Therapeutics from $105.00 to $125.00 and gave the company a “buy” rating in a research note on Wednesday, July 22nd. Wall Street Zen upgraded shares of Monopar Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Zacks Research raised shares of Monopar Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 13th. Finally, Piper Sandler set a $105.00 target price on Monopar Therapeutics in a report on Tuesday, June 2nd. Three research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Monopar Therapeutics has an average rating of “Buy” and an average price target of $117.42.

Check Out Our Latest Report on Monopar Therapeutics

About Monopar Therapeutics

(Get Free Report)

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.